There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.

Biologics Quality Control: The Growing Need for Accessible Proteomics

The emergence of mRNA vaccines and cell and gene therapies has pushed innovation in analytical methods.

Emerging Therapies Drive Analytical Advancements

Effective analytics will eliminate failures, deviations, and non-conformances.

 Analyzing Exabytes

Topic

Articles

Biocad and Sothema Labs have partnered to release cancer-treating biosimilars into the North African market.

Biocad Announces New Manufacturing Site in North Africa

Binding Site has introduced a number of new monoclonal antibodies targeting infectious diseases, including cytomegalovirus, hepatitis (A, B, C, and D), herpes, human immunodeficiency virus (HIV), rubella, and toxoplasma. 

Binding Site Expands mAb Portfolio

The acquisition gives GE Healthcare access to a nanofiber-based platform purification technology that can offer improvements in biopharmaceutical productivity.

GE Healthcare Completes Acquisition of Bioprocessing Start-Up

Kevin Hill heads the marketing efforts at Quality Scales Unlimited in Byron, CA, Kevin@scalesu.com

Understanding what affects a measurement and implementing appropriate procedures will aid weighing accuracy.

Best Weighing Practices in the Pharmaceutical Industry

Ontruzant is the first biosimilar of Roche’s Herceptin (trastuzumab) to be approved in Europe. 

Samsung Bioepis Receives Approval for First Trastuzumab Biosimilar, Ontruzant, in Europe

The agency has approved a biologic-based new molecular entity for treating hemophilia A and has expanded the indication for a leukemia drug to now treat a common form of non-Hodgkin lymphoma.

FDA Approves Roche’s Hemophilia A Biologic and Expands Indication for Leukemia Drug

MasterControl has added three new cloud-based analytical solutions to its MasterControl Version 11.7 software for clinical managers and regulatory/submissions professionals.

Integrated Analytical Software Solutions for Clinical and Regulatory Processes

As part of the deal, J&J’s Janssen will pay an upfront payment of $50 million to research, develop, and commercialize up to six bispecific antibodies.

J&J and Zymeworks in Bispecific Antibody Pact Worth Nearly $1.5 Billion

The company’s new modules offer scalable single-pass diafiltration and were exclusively showcased during its Leadership Forum series in Westborough, MA.

Pall Debuts New Inline Diafiltration Modules for Continuous Bioprocessing

The use of therapeutic vaccines presents a new way to manage diseases, such as cancer and sexually transmitted diseases.

Analytics

Biologics Quality Control: The Growing Need for Accessible Proteomics

Emerging Therapies Drive Analytical Advancements

Analyzing Exabytes